Media stories about Genomic Health (NASDAQ:GHDX) have trended somewhat negative recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Genomic Health earned a news sentiment score of -0.05 on Accern’s scale. Accern also gave news headlines about the medical research company an impact score of 45.5633483520665 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
Top 5 Medical Stocks To Buy For 2019: AMTEK, Inc.(AME)
Advisors' Opinion:- [By Joseph Griffin]
AMETEK (NYSE:AME) had its target price upped by BMO Capital Markets from $92.00 to $93.00 in a report issued on Wednesday morning. BMO Capital Markets currently has an outperform rating on the technology company’s stock.
- [By Shane Hupp]
Mountain Pacific Investment Advisers Inc. ID trimmed its stake in shares of AMETEK, Inc. (NYSE:AME) by 1.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 533,274 shares of the technology company’s stock after selling 5,917 shares during the quarter. AMETEK accounts for 4.2% of Mountain Pacific Investment Advisers Inc. ID’s portfolio, making the stock its 3rd largest holding. Mountain Pacific Investment Advisers Inc. ID’s holdings in AMETEK were worth $40,513,000 as of its most recent SEC filing.
- [By Max Byerly]
Legal & General Group Plc lowered its stake in shares of AMETEK, Inc. (NYSE:AME) by 6.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,080,233 shares of the technology company’s stock after selling 73,951 shares during the quarter. Legal & General Group Plc owned about 0.47% of AMETEK worth $82,065,000 at the end of the most recent quarter.
- [By Max Byerly]
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
Get AMETEK alerts: Haydon Kerk Motion Solutions Releases 2018 Linear Motion Catalog and Design Guide (news.thomasnet.com) Global Electric Motor Market 2018 – Ametek, Inc., Bosch Group, Emerson Electric Co., Hitachi, Ltd. (journalcommunication.com) Grass isn’t always greener with these two names: AMETEK, Inc. (AME), CYS Investments, Inc. (CYS) (fintelegraph.com) Global Motor Vehicle Sensors Market 2018 – Agilent Technologies, Ametek Inc., Analog Devices Inc., Ashcroft … (globaltopkeyplayers.com) Why these Stocks Could Be Off to the Races? AMETEK, Inc. (AME) and Simon Property Group, Inc. (SPG) (nmsunews.com)Shares of AME traded down $0.49 on Thursday, reaching $74.84. 887,300 shares of the stock traded hands, compared to its average volume of 1,284,629. The stock has a market cap of $17.51 billion, a PE ratio of 28.67, a P/E/G ratio of 2.42 and a beta of 1.26. The company has a current ratio of 1.69, a quick ratio of 1.18 and a debt-to-equity ratio of 0.45. AMETEK has a 12 month low of $59.56 and a 12 month high of $79.32.
- [By Logan Wallace]
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
Get AMETEK alerts: Ac Power Source Supply Market 2018 Global Share- AMETEK Programmable Power, Pacific Power Source and … (theexpertconsulting.com) The Whispers about AMETEK, Inc. (AME) and Omeros Corporation (OMER) (nmsunews.com) Global Neutron Generators Market Analysis 2018 Del Mar Photonics, VNIIA, AMETEK ORTEC, Adelphi Technology … (theexpertconsulting.com) AMETEK, Inc. (AME): Most Popular stock: (stockquote.review) Ametek granted partial judgment in alleged ground contamination cased filed by mobile home parks’ owners (norcalrecord.com)Several research firms have recently commented on AME. Morgan Stanley lifted their price target on shares of AMETEK from $76.00 to $79.00 and gave the company an “equal weight” rating in a research report on Thursday, May 3rd. BMO Capital Markets lifted their price target on shares of AMETEK from $90.00 to $92.00 and gave the company an “outperform” rating in a research report on Thursday, May 3rd. Zacks Investment Research lowered shares of AMETEK from a “buy” rating to a “hold” rating in a research report on Thursday, April 12th. DA Davidson began coverage on shares of AMETEK in a research report on Thursday, April 12th. They set a “buy” rating and a $85.00 price target on the stock. Finally, ValuEngine raised shares of AMETEK from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $82.00.
- [By Ethan Ryder]
Rhumbline Advisers grew its holdings in shares of AMETEK, Inc. (NYSE:AME) by 3.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 450,212 shares of the technology company’s stock after purchasing an additional 13,189 shares during the quarter. Rhumbline Advisers’ holdings in AMETEK were worth $32,487,000 at the end of the most recent reporting period.
Top 5 Medical Stocks To Buy For 2019: Mallinckrodt plc(MNK)
Advisors' Opinion:- [By Joseph Griffin]
An issue of Mallinckrodt PLC (NYSE:MNK) debt rose 0.6% against its face value during trading on Monday. The debt issue has a 5.75% coupon and will mature on August 1, 2022. The bonds in the issue are now trading at $94.50 and were trading at $91.75 last week. Price moves in a company’s debt in credit markets sometimes anticipate parallel moves in its stock price.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Mallinckrodt (MNK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Dan Caplinger]
Wall Street moved lower on Thursday, with the Dow Jones Industrial Average suffering a 201-point decline. Stocks took their cues from the bond market, where bond prices dropped sharply in response to extremely strong U.S. economic data. For years, the economic expansion has given bond investors a Goldilocks scenario, in which growth was solid but not so sharp as to cause negative side effects, such as inflation. Now, stronger signals could force the Federal Reserve to raise interest rates more aggressively than previously thought, and that could hurt the markets. Several individual companies also suffered from bad news that sent their shares lower. Mallinckrodt (NYSE:MNK), International Speedway (NASDAQ:ISCA), and LGI Homes (NASDAQ:LGIH) were among the worst performers on the day. Here's why they did so poorly.
Top 5 Medical Stocks To Buy For 2019: STARWOOD PROPERTY TRUST, INC.(STWD)
Advisors' Opinion:- [By Logan Wallace]
Dynamic Technology Lab Private Ltd bought a new stake in Starwood Property Trust, Inc. (NYSE:STWD) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 25,758 shares of the real estate investment trust’s stock, valued at approximately $560,000.
- [By Max Byerly]
JPMorgan Chase & Co. initiated coverage on shares of Starwood Property Trust (NYSE:STWD) in a report issued on Friday, Marketbeat.com reports. The brokerage set an “overweight” rating and a $23.00 price target on the real estate investment trust’s stock. JPMorgan Chase & Co.’s target price would suggest a potential upside of 5.12% from the company’s current price.
- [By Joseph Griffin]
Strs Ohio acquired a new stake in shares of Starwood Property Trust, Inc. (NYSE:STWD) in the second quarter, HoldingsChannel.com reports. The firm acquired 28,456 shares of the real estate investment trust’s stock, valued at approximately $617,000.
- [By Motley Fool Transcribers]
Starwood Property Trust Inc (NYSE:STWD)Q4 2018 Earnings Conference CallFeb. 28, 2019, 10:00 a.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
Top 5 Medical Stocks To Buy For 2019: MuniVest Fund, Inc.(MVF)
Advisors' Opinion:- [By Max Byerly]
BlackRock MuniVest Fund Inc. (NYSEAMERICAN:MVF) declared a monthly dividend on Thursday, September 6th, Wall Street Journal reports. Stockholders of record on Friday, September 14th will be paid a dividend of 0.041 per share by the investment management company on Monday, October 1st. This represents a $0.49 annualized dividend and a dividend yield of 5.57%. The ex-dividend date of this dividend is Thursday, September 13th.
Top 5 Medical Stocks To Buy For 2019: Cellectis S.A.(CLLS)
Advisors' Opinion:- [By Stephan Byrd]
Shares of Cellectis SA (NASDAQ:CLLS) have earned an average recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $42.00.
- [By Ethan Ryder]
Media headlines about Cellectis (NASDAQ:CLLS) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellectis earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 47.0875412676142 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
No comments:
Post a Comment